The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile.
Nicola SquillaceElena Delfina RicciBarbara MenzaghiGiuseppe Vittorio De SocioSimone PasseriniCanio MartinelliMaria Sabrina MameliPaolo MaggiFalasca KatiaLaura CordierBenedetto Maurizio CelesiaElena SalomoniAntonio Di BiagioGiovanni Francesco PellicanòBonfanti Paolonull nullPublished in: Drug design, development and therapy (2020)
A significant reduction of liver enzymes was observed after switching from TDF to TAF, especially in subjects with initial level of ALT >40 IU/L. Glucose, TC, HDL-C, and LDL-C increased, with no effect on cardiovascular risk scores.